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RESEARCH Open AccessFifteen years of heroin-assisted treatment
in a Swiss prison—a retrospective cohort
study
Michael Liebrenz1* , Alex Gamma1, Anna Buadze2, Roman Schleifer1, Stéphanie Baggio1,3, Bruce Schwartz4,
Andres Schneeberger4,5† and Ambros Uchtenhagen6†Abstract
Background: In the context of the current US opioid crisis and the compelling fact that a quarter to a third of all
those addicted to heroin pass through its prisons and jails each year, the care of incarcerated opioid-using
individuals (OUI) needs to be improved.
Aims: Little has been published on the effectiveness or outcomes of heroin-assisted treatment (HAT), a treatment
option for severely dependent OUI delivered in a prison setting. The aim of this study was therefore to evaluate
such treatment since its implementation. The primary objective was to investigate whether heroin-assisted
treatment was associated with severe detrimental health outcomes. The secondary objective was to compare the
heroin-assisted treatment group with the general prison population in terms of occupational functioning.
Design: Retrospective cohort study
Setting: An open prison with 120 places
Subjects: Data on 1885 male prisoners with a total of 2239 imprisonment periods between 2000 and 2015 was
available. Ninety-seven inmates in heroin-assisted treatment were compared with 1788 inmates from the general
prison population (reference group).
Measurements: Mortality, medical complications (including overdoses), and work performance (days worked, sick
days, and monthly wages earned).
Findings: Inmates receiving HAT were on average 1 year younger (33.8 vs. 34.9 years), had longer prison stays (7.3
vs. 3.0 months), were more often of Swiss nationality (68.0% vs. 28.9%), and had committed more drug- and
property-related offenses (49.5% vs. 23.2% and 63.9% vs. 38.3%, respectively) compared to the reference group. No
serious heroin-related medical complication occurred during the 15-year window of observation among inmates
with heroin-assisted treatment. Their work performance was comparable to that of the reference group.
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Conclusions: This study shows that heroin-assisted treatment can be a valuable treatment option for severely
dependent OUI during imprisonment, can be delivered safely by prison health staff over extended periods of time,
and allows OUI in treatment to achieve work performance rates comparable to that of the general prison
population.
Keywords: Heroin-assisted treatment, Prison, Jail, Incarceration, Opioid crisis, Opioid-using individuals, Social
functioningIntroduction
In the context of the current opioid crisis in the USA,
and against the backdrop that a quarter to a third of all
US residents addicted to heroin pass through US prisons
and jails each year [1], care for incarcerated opioid-using
individuals (OUI) has become a focus of scientific inter-
est. A smarter war on drugs [2], with addiction and
overdose initiatives that address the current opioid epi-
demic and particularly envisage a criminal justice-based
continuum of care for OUI, has been called for [3]. This
implies a need for studies that not only evaluate medica-
tions used to treat opioid use disorders (OUD) in certain
populations, but also develop better ways of assessing
the outcomes of relevant therapeutic interventions [4].
Similar considerations, demands, and research ques-
tions arose some time ago in Switzerland, a federally
governed European country. At the height of its heroin
epidemic in the late 1980s, Switzerland had an estimated
30,000–40,000 OUI, i.e., 0.5–0.8% of the total population
[5]. The drug policy response to this crisis was inconsist-
ent, fluctuating between liberal and repressive ap-
proaches. After conditions had deteriorated to the point
where open drug scenes existed in several Swiss cities, a
national harm-reduction policy was adopted in 1991. It
formally permitted the implementation of low-threshold
medication-assisted treatment (MAT) with methadone
and (later) buprenorphine, needle and syringe exchange
services, and supervised consumption rooms [6]. Se-
verely dependent OUI over the age of 18, who had failed
MAT (defined as using additional, illegally obtained opi-
oids despite receiving prescription medication) at least
twice, were eligible to receive heroin-assisted treatment
(HAT). Permission and control mechanisms were put
into effect by the Federal Office of Public Health [7].
Under HAT, illegal “street heroin” is replaced by medic-
ally prescribed, pharmaceutically pure diacetylmorphine.
HAT is more strictly regulated than MAT and does not
allow take-home administration. Thus, HAT restricts OUI
in everyday life more than MAT does and represents a
therapeutic last resort for a seriously ill subpopulation.
This is also reflected in the distribution of treatment fre-
quencies: Of the approx. 19,400 OUI in treatment today,
over 90% receive MAT, while only 1752 or about 8% re-
ceive HAT with diacetylmorphine [8].In Switzerland, HAT was first evaluated as a treatment
alternative in pilot trials in the 1990s [9]. The positive
findings were later confirmed in other countries as well
[10–12].
Since 1999, HAT has been introduced as a limited
medical application in specialized outpatient clinics [13,
14]. In 2008, harm reduction and heroin prescription
were legally anchored in the narcotics law [15]. Since a
large number of OUI were coming into contact with the
criminal justice system via drug-related crime and/or vi-
olations of the narcotics law, a paradigm shift occurred
in the 1990s, enabling the start and continuation of
MAT during detention in jail and/or prison. In addition,
two Swiss prisons (Schöngrün penitentiary in 1995 and
Realta penitentiary in 2000/2001) also made it possible
for inmates to start and continue HAT. After the closure
of the former in 2015 [16], there is, to the authors’
knowledge, only one correctional facility worldwide that
offers HAT to severely dependent inmates during
incarceration.
In view of the extreme paucity of data on the out-
comes associated with HAT when delivered in prison
settings, the aim of this study was to evaluate HAT since
its implementation in the Realta prison. The main ob-
jective of the study was to investigate whether HAT was
associated with detrimental health outcomes, including
death, overdose, and medical complications. The sec-
ondary objective was to compare the HAT group with
the general prison population (reference group) in terms
of occupational functioning. The findings of this study
should thus serve to provide a better understanding of
HAT use in prison settings, identify benefits and risks
associated with the use of HAT in a prison population,
and inform clinical practice on the functioning level of
OUI using HAT during periods of imprisonment.Materials and methods
Study design and setting
This was a retrospective cohort study including inmates
from the Realta prison, Switzerland, who either received
HAT or did not (i.e., inmates from the general prison
population serving as the reference group, labeled “non-
HAT” below). It is an open prison with 120 places, of
which six were treatment slots for HAT in 2000; there
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male OUI who have been sentenced to imprisonment.
Treatment can either be continued on the basis of a
medical referral or initiated during the prison term. Her-
oin is delivered twice daily between 7:00 and 7:15 a.m.
and 6:30 and 6:45 p.m. by two nurses. The detainees ad-
minister the heroin themselves either intravenously,
intramuscularly, or orally in a dispensing room (pictures
available), where they are monitored from the adjoining
room.
Work is a mandatory part of imprisonment in Realta.
Most jobs are assigned to inmates by staff, with the ex-
ception of work on weekends (e.g., in the kitchen or in
the fields), which is done on a volunteer basis. Also, barn
work is considered more demanding (requiring more
physical strength as well as getting up early) than other
kinds of work and is preferentially assigned to more mo-
tivated or capable inmates.Subjects
In 2016, data on all inmates imprisoned between 2000
and 2015 were extracted from the electronic prison data-
base. One hundred eleven prisoners had received HAT
during the study period. Most inmates had only one
prison term during the observation period, but some
had several terms (Table 1). Subjects with several prison
terms were allocated to the HAT group if they had re-
ceived HAT during at least one term. It turned out,
however, that all HAT participants with several terms
had received HAT in every single one of their terms.
About half (46.4%) of the subjects receiving HAT add-
itionally received methadone, and in 4 (4.1%) cases,
HAT was stopped and replaced with morphine or
buprenorphine. Individuals receiving only MAT were ex-
cluded from the final sample because of the small sam-
ple size (n = 14) and are thus not part of the final HAT
group. The final number of subjects in the HAT group
was therefore n = 97. All non-HAT reference subjects (n
= 1885) were included in the study. The non-HAT
group did not include individuals who had participated
in MAT during the observation period. Both groups
were already naturally matched on sex and age, and fur-
ther matching was not attempted.
The eligibility criteria for HAT during detention are
the following:
– At least 2 years of demonstrable heroin addiction
– At least two failed recognized treatment attempts
(such as a MAT)
– Medical, psychological, or social deficits due to
opioid drug use
– Consent of the referring legal authority (probation
and correctional services)Measures
Medical information
In the HAT group, we collected information on mortal-
ity, overdoses, and other medical complications (health
and safety issues during and after heroin distribution)
from prison medical records. In accordance with previ-
ous studies, non-fatal heroin overdose was defined as
any of the following symptoms: suppressed breathing,
turning blue, collapsing, losing consciousness, and being
unable to be roused [17, 18].
Occupational functioning
Work performance was documented by prison staff
using six variables: number of days worked, number of
days sick, number of weekend days worked, number of
days of barn work, salary (all per month), and occupa-
tional accidents.
Control variables
Other variables recorded by prison staff included age,
sex, nationality, dates of admission and discharge, use of
psychiatric services, and index offense.
Statistical analysis
Analyses were performed on the subject level, aggregat-
ing, if necessary, over multiple prison terms. Aggregation
consisted of summing frequencies of categorical vari-
ables over all of a subject’s prison terms and by sum-
ming continuous variables and computing per-month
averages based on the total length of a subject’s
incarceration.
Between-group comparisons of frequencies used chi-
squared tests, while Kruskal-Wallis tests were applied to
continuous variables due to their mostly non-normal
distributions. Bonferroni correction for multiple com-
parison was applied to sets of variables related to a com-
mon subject area. For the outcomes of secondary
interest, multivariable analyses were run. For variables
showing a normal distribution (disregarding the excess
zeros), we used a linear model; for those showing
Poisson-like distributions, we used an exponential
model. Predictors included group (HAT or non-HAT),
age, Swiss nationality, use of psychiatric services, length
of prison term, and the date of the mid-point of the
prison term. An excess of zeros was present for all vari-
ables, prompting the use of hurdle models [19–21]. The
analysis was conducted on the level of subjects. How-
ever, robust standard errors were calculated to account
for the clustering of prison terms within subjects [21–
26]. Models were implemented using Stata’s churdle
command.
Missing values were not imputed. There were no miss-
ing values for the primary outcomes and 0.1% for the
secondary outcome. Percentages of missing values were
Table 1 Basic characteristics of prison inmates
Total Non-HAT HATa Missing, N (%) pb pBonf
c
N inmates (%) 1885 (100) 1788 (94.9) 97 (5.2) 0 (0) n.a. n.a.
Prison terms
• N 1591 inmates: 1 term
228 inmates: 2 terms
52 inmates: 3 terms
10 inmates: 4 terms
3 inmates: 5 terms
1 inmate: 6 terms
Total: 2239 terms
1529 inmates: 1 term
204 inmates: 2 terms
43 inmates: 3 terms
8 inmates: 4 terms
3 inmates: 5 terms
1 inmates: 6 terms
Total: 2119 terms
62 inmates: 1 term
24 inmates: 2 terms
9 dinmates: 3 terms
2 inmates: 4 terms
Total: 120 terms
0 (0) n.a. n.a.
• Total length [months], median (IQR, min–max) 3.1 (5.39, 0.0–101.0) 3.0 (4.94, 0.0–101.0) 7.3 (10.71, 0.3–40.9) 0 (0) 0.000 n.a.
Sex, N (%), male 1885 (100) 1788 (100) 97 (100) 0 (0) n.a. n.a.
Age, mean (SD, min–max)d 33.8 (10.83, 17.0–85.0) 33.8 (11.01, 17.0–85.0) 34.9 (6.61, 22.0–52.0) 0 (0) 0.000 n.a.
Nationality, N (%), Swiss 583 (30.9) 517 (28.9) 66 (68.0) 349 (15.6) 0.000 n.a.
Index offense, N (%), with ≥ 1 offense 152 (6.8)
• Drug 462 (24.5) 414 (23.2) 48 (49.5) 0.000 0.000
• Traffic, lighte 216 (11.5) 205 (11.5) 11 (11.3) 0.97 1.0
• Traffic, severef 100 (5.3) 99 (5.5) 1 (1.0) 0.05 0.9
• Arson 7 (0.4) 7 (0.4) 0 (0.0) 0.54 1.0
• Kidnapping 3 (0.2) 3 (0.2) 0 (0.0) 0.69 1.0
• Sex 41 (2.2) 40 (2.2) 1 (1.0) 0.43 1.0
• Homicide/manslaughter 21 (1.1) 1 (1.1) 1 (1.0) 0.94 1.0
• Property 747 (39.6) 685 (38.3) 62 (63.9) 0.000 0.000
° Fraud 122 (6.5) 115 (6.4) 7 (7.2) 0.76 1.0
° Theft 597 (31.7) 541 (30.3) 56 (57.7) 0.000 0.000
° Robbery/extortion 75 (4.0) 65 (3.6) 10 (10.3) 0.001 0.018
° Otherg 108 (5.7) 100 (5.6) 8 (8.2) 0.27 1.0
• Assault 173 (9.2) 162 (9.1) 11 (11.3) 0.45 1.0
• Weaponsh 24 (1.3) 21 (1.2) 3 (3.1) 0.10 1.0
• Obstruction of justicei 82 (4.4) 75 (4.2) 7 (7.2) 0.16 1.0
• Otherj 752 (39.9) 730 (40.8) 22 (22.7) 0.000 0.000
• Total violent crimesk 289 (15.3) 270 (15.1) 19 (19.6) 0.23 1.0
• Grand total 1674 (88.8l) 1586 (88.7l) 88 (90.7l) 0.54 1.0
HAT heroin-assisted treatment, IQR interquartile range, min minimum, max maximum, N number, SD standard deviation
aIncludes heroin with or without other substituents (46.4% persons with methadone and 4.1% with morphine or buprenorphine)
bKruskal-Wallis test for period length, t test for age, Pearson’s chi-squared test for frequencies otherwise
cBonferroni-corrected p value correction only applied to offense-related variables
dAge is at the middle of an inmate’s imprisonment period. In the case of several stays, the mean is taken
eIncludes driving without a license and violations of traffic and transportation laws
fIncludes drunk driving and hit-and-run
gIncludes handling stolen goods and computer fraud
hIncludes any violation of weapons laws
iIncludes violence or threats against public authorities or officials, contempt of official orders, prevention of an official action
jIncludes property damage, violations of immigration laws, refusal to present personal identification, libel/slander, violations of animal protection laws,
panhandling, and others
kIncludes homicide, manslaughter, assault, sex offenses, robbery, and blackmail
lThe numbers do not sum to 100% due to missing values
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but there were no missing values for the use of psychi-
atric services. Results of a power analysis for the chi-
squared and Kruskal-Wallis tests are available in the
supplement. R version 3.4.2 and Stata version 14.2 were
used for analysis.Results
Preliminary analyses
In total, there were 1885 inmates, 97 (5.2%) HAT and
1788 (94.9%) non-HAT. The mean age was 33.8 years,
with about a year’s difference between the groups. Swiss
was by far the most frequent nationality in the two
Liebrenz et al. Harm Reduction Journal           (2020) 17:67 Page 5 of 8groups. HAT subjects were significantly more likely to
be Swiss (68.0%) than non-HAT subjects (28.9%). The
median length of imprisonment was 3.1 months and
ranged from a few days to over 8 years. Compared to
subjects receiving HAT, non-HAT subjects had shorter
stays (3.0. vs. 7.3 months; Table 1).
Apart from the unspecific category “other,” the most
frequent reason for imprisonment was a property-
related offense (≥ 35 % in both groups), of which theft
was the most common (> 35% of all property-related of-
fenses). A drug-related offense was the second most fre-
quent reason for imprisonment (> 20% in both groups).
Assault had a 10% frequency in both groups, while vio-
lent crimes made up 15–20% of all offenses. Compared
to non-HAT inmates, HAT inmates had committed sta-
tistically significantly more drug-related offenses (49.5%
vs. 23.2%), property-related offenses (63.9% vs. 38.3%,
with theft also being more frequent at 57.7% vs. 30.3%),
and robbery and extortion offenses (10.3% vs. 3.6%).
They were less often found to have committed severe
traffic offenses (1.0% vs. 5.5%) and “other” crimes (22.7%
vs. 40.8%; Table 1).
Of HAT subjects, 22.7% had at least one consultation
with the consiliary psychiatric service, whereas only 1.5%
of the reference group subjects did.
Primary objective: mortality, overdoses, and other
medical complications in the HAT group
No opioid overdose death, no non-fatal overdose, and
no serious medical complications were observed in the
HAT group at any time. In one case, a HAT subject
showed a “slight clouding of consciousness for 10 min
after drug administration,” but this needed no further
medical intervention and no treatment with naloxone
hydrochloride, for example. No overdose-related mor-
bidity was observed including rhabdomyolysis, pulmon-
ary symptoms (e.g., pneumonia, edema), cardiac
arrhythmia, seizures, and paralysis. No safety issue dur-
ing or after heroin distribution was ever reported.
Secondary objective: occupational functioning
Inmates worked for a median of 18.6 days per month
and had a median of zero sick days. The median number
of work days was slightly higher (18.7 vs. 17.0), and the
number of sick days lower (0.0 vs. 1.0) in the non-HAT
group. HAT subjects, however, had more days of barn
work (both medians zero, means 3.4 vs. 1.9) and a higher
salary (36.6 CHF vs. 33.0 CHF). To be maximally in-
formative, Table 2 shows the results broken down by
categories of days. eTable 1 in the supplement shows the
results in terms of medians.
Multivariable analyses revealed only a few effects that
were of both practical and statistical significance: HAT
was associated with about one and a half fewer workdays, about one and a half more sick days, and about 1
day less of weekend work. Being of Swiss nationality was
associated with about half a day less of being sick and
about one additional day of barn work. Five additional
months of imprisonment were associated with one add-
itional work day (eTable 2 in the Supplement).
No occupational accidents associated with participa-
tion in HAT were recorded during the observation
period.
Missingness on nationality and index offense had a
number of sizeable and statistically significant effects on
work-related outcomes and other variables, notably on
the monthly number of work days, weekend days at
work, monthly salary, and use of psychiatric services
(eTables 3 & 4 in the Supplement).
Discussion
Fifteen years after the introduction of heroin-assisted
treatment for incarcerated opioid-using individuals in a
Swiss open prison, we found no evidence for increased
mortality, overdoses, or severe medical complications. In
fact, over the time period evaluated, no drug-related
death occurred in inmates receiving HAT.
Here, it should be emphasized that this was an open
prison setting, i.e., inmates are given the opportunity to
leave the prison during the day and work offsite, thus in-
creasing their likelihood of being exposed to illegal street
opioids. Various studies have shown that the mortality
rate of OUI immediately after release from closed prison
without MAT is increased and remains at an elevated
level [27–29]. The elevated risk of fatal overdoses in this
population has been linked to the loss of tolerance for
opioids during incarceration, in combination with a lack
of psychoeducation about the consequences of resump-
tion of opioid use in unchanged dosages [30, 31]. In con-
trast, the introduction and continuation of MAT are
associated with a reduction in mortality after release
from prison during community re-entry [32, 33]. Our
findings in an open prison complement these reports
and underline that this protection holds true even for se-
verely dependent OUI with HAT, who were considered
unresponsive to MAT.
On measures of work performance, which can be
understood as a proxy for occupational and social func-
tioning [34–36], we found comparable levels of days
worked, sick days, and monthly salary between OUI in
treatment with HAT and the general prison population.
This finding is surprising for three reasons. First, in-
mates receiving HAT represent a group of severely
dependent OUI who have failed other forms of treat-
ment, including MAT. Significant impairments in social
and work performance for severely addicted individuals
are well documented elsewhere [37–39]. Second, in-
mates who received HAT seemed to suffer to a
Table 2 Work performance per month of imprisonment
Total Non-HAT HATa Missing, N (%) pb pBonf
c
N (%) 1885 (100) 1788 (94.9) 97 (5.2) 0 (0) n.a.
Salary [Swiss francs], median (IQR, min–max) 33.5 (13.28, 0.0–578.3) 33.0 (13.36, 0.0–578.3) 36.6 (12.04, 0.0–72.2) 3 (0.13) 0.001 0.005
N work days N (%) N (%) N (%) 3 (0.13) 0.0005 0.0025
0 170 (9.0) 165 (9.2) 5 (5.2)
1–4 57 (3.0) 47 (2.6) 10 (10.3)
5–9 137 (7.3) 118 (6.6) 19 (19.6)
10–14 196 (10.4) 186 (10.4) 10 (10.3)
15–19 715 (38.0) 685 (38.4) 30 (30.9)
20–24 562 (29.9) 539 (30.2) 23 (23.7)
25+ 45 (2.4) 45 (2.5) 0 (0.0)
N sick days N (%) N (%) N (%) 3 (0.13) 0.0005 0.0025
0 1403 (74.6) 1354 (75.9) 49 (50.5)
1–4 316 (16.8) 285 (16.0) 31 (32.0)
5–9 86 (4.6) 76 (4.3) 10 (10.3)
10–14 38 (2.0) 33 (1.9) 5 (5.2)
15–19 29 (1.5) 27 (1.5) 2 (2.1)
20+ 10 (0.5) 10 (0.6) 0 (0.0)
N weekend days at work N (%) N (%) N (%) 3 (0.13) 0.03 0.15
0 1521 (80.8) 1437 (80.5) 84 (86.6)
1–4 207 (11.0) 195 (10.9) 12 (12.4)
5+ 154 (8.2) 153 (8.6) 1 (1.0)
N days barn work N (%) N (%) N (%) 3 (0.13) 0.001 0.005
0 1628 (86.5) 1556 (87.2) 72 (74.2)
1–4 44 (2.3) 37 (2.1) 7 (7.2)
5–9 37 (2.0) 34 (1.9) 3 (3.1)
10–14 31 (1.6) 30 (1.7) 1 (1.0)
15–19 61 (3.2) 54 (3.0) 7 (7.2)
20+ 81 (4.3) 74 (4.2) 7 (7.2)
HAT heroin-assisted treatment, IQR interquartile range, max maximum, min minimum, N number
aIncludes heroin with or without other substituents (46.4% persons with methadone and 4.1% with morphine or buprenorphine)
bKruskal-Wallis test for salary, otherwise chi-squared test
cBonferroni-corrected p values
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ing mental disorders, as reflected by the fact that they
were referred to or sought out psychiatric consultation
15 times more often than non-HAT inmates. Mental ill-
ness with a co-morbid substance use disorder is also
known to decrease levels of work performance [40].
Third, HAT-receiving inmates suffered to a greater ex-
tent from physical illnesses and infectious diseases, as in-
dicated by the higher frequency of pain, gastrointestinal,
and antiviral medications prescribed. Periods of physical
illness are also associated with an increased risk of in-
ability to work [41].
It was equally surprising that no occupational acci-
dents associated with participation in HAT were re-
ported during the observation period. From theperspective of legal authorities, next to fears about diver-
sion of substances (stealing and smuggling drugs), the
risk of accidental overdose and concerns over problems
with the operation of machinery had been major obsta-
cles to the introduction of MAT or HAT in Swiss
prisons.
Due to the closure of the Schöngrün penitentiary in
2015, we could not evaluate its HAT program. However,
after the introduction of HAT in conjunction with other
harm-reduction approaches (e.g., needle exchange pro-
grams for injecting OUI) in Schöngrün, the number of
fatal and non-fatal heroin overdoses among incarcerated
OUI fell dramatically over a period of 9 years [42].
A recent meta-analysis of randomized trials of HAT
for refractory heroin addiction among non-incarcerated
Liebrenz et al. Harm Reduction Journal           (2020) 17:67 Page 7 of 8OUI found that “heroin prescribing, as part of the highly
regulated regimen, is a feasible and effective treatment
for a particularly difficult-to-treat group of heroin-
dependent patients who have not responded to standard
treatments such as oral methadone maintenance or resi-
dential rehabilitation” [43]. The meta-analysis focused
on treatment retention, illegal heroin use, mortality, and
side effects and found improvements in mental and
physical health as well as in social functioning [44]. Our
observational study underscores these findings and pro-
vides evidence that these results also hold true for HAT
administered to OUI under conditions of imprisonment.
Additionally, we are able to report that the work per-
formance and earnings of prisoners in a HAT program
were comparable to the general prison population. This
finding is a further indication of HAT’s usefulness in
terms of improvements in the functioning and rehabili-
tation of affected individuals.
Brinkley-Rubinstein et al. [3] correctly point out that
there is great heterogeneity within the prison system;
thus, “what is possible in a rural (…) county will not al-
ways be comparable to what can be implemented in
some big urban environments,” and thus, our findings
from Switzerland might be of less relevance to the USA,
which would constitute an important limitation. How-
ever, our data—in conjunction with the existing litera-
ture—provides three arguments for the introduction of a
“criminal justice continuum for opioid users”: first, it
shows that there are treatment options available even for
severely dependent OUI and that those forms of treat-
ment do not lead to increased mortality during periods
of incarceration; second, those treatments can be deliv-
ered safely by prison health staff over extended periods
of time; third, OUI in treatment achieve a work perform-
ance comparable to the general prison population. The
last economic argument might prove to be of relevance
in a correctional system which attaches great importance
to the work activities of detainees [45].
Limitations
Our study has important limitations. Sample sizes, espe-
cially the relatively small group of inmates enrolled in
HAT, limited detectable effects (see power analysis in sup-
plement). This limitation is inherent, as the HAT group
actually constitutes the entire current population of
heroin-treated prisoners in Switzerland. There were some
sizeable differences in work performance and other vari-
ables between subjects with and without missing data on
nationality and index offenses. This means that the multi-
variable associations (reported in the supplement) be-
tween work performance on one hand, and nationality
and index offense on the other, are less reliable. The main
analyses that compare outcomes between HAT subjects
and reference subjects are, however, unaffected.Conclusions
This study shows that heroin-assisted treatment can be a
valuable treatment option for severely dependent opioid-
using individuals during periods of imprisonment. It also
shows that HAT can be delivered safely by prison health
staff over extended periods of time and that opioid-using
individuals in such a treatment program achieve work
performance comparable to that of the general prison
population.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12954-020-00412-0.
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